Novartis AG ADR (NVS)vsSerina Therapeutics Inc (SER)
NVS
Novartis AG ADR
$162.55
+0.38%
HEALTHCARE · Cap: $303.67B
SER
Serina Therapeutics Inc
$1.38
-16.36%
HEALTHCARE · Cap: $49.28M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
SER
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$162.55
$66.99 premium
Intrinsic value data unavailable for SER.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Revenue surging 154.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while SER is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 27/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This technology significantly enhances the efficacy of therapeutic agents, positioning Serina at the forefront of the biopharmaceutical industry. With a promising pipeline of product candidates and strategic partnerships, the company is well-equipped to drive sustainable growth and deliver impactful healthcare solutions, all while creating substantial value for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?